title: Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models.
abstract: The aim of our study was to enhance the bioavailability of ranolazine by using herbal-bioenhancer quercetin in rats and to study the role of P-glycoprotein (P-gp) in vitro models. In single dose study (SDS), rats were divided into four groups, Group I was treated with 0.5% sodium carboxy methyl cellulose (SCMC), Group II was treated with ranolazine (14 mg/kg), Group III was treated with quercetin (20 mg/kg) and Group IV was treated with both ranolazine and quercetin. The blood samples were collected at 0.5, 1, 2, 3, 4, 6, 8 and 12 h, and the concentration of ranolazine in the plasma was estimated by reverse phase high performance liquid chromatography (RP-HPLC) method. In multiple dose study (MDS), rats were treated with same drugs for 7 days. On 8th day, the concentration of ranolazine in plasma was estimated. In vitro study performed on the rat and chick intestinal sacs to study the intestinal transport of ranolazine in the presence and absence of quercetin and verapamil (P-gp-inhibitor). Quercetin increased the peak concentration (Cmax) of ranolazine from 254 ± 8.45 to 324 ± 10.21 and 331 ± 9.65 ng/mL in SDS and MDS, respectively. Quercetin also increased area under the curve (AUC) of ranolazine from 1565.12 ± 52.24 to 2016.98 ± 142.65 and 2070.85 ± 271.60 ng/mL/h in SDS and MDS, respectively. The transport of ranolazine from mucosal side to serosal side was increased in presence of quercetin. Quercetin is an inhibitor of CYP3A4 and P-gp. So it increased the AUC and Cmax of ranolazine.
authors: Department of Pharmacology, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.
authors: P Ravindra
authors: PR
authors: Babu
authors: K Naveen
authors: KN
authors: Babu
authors: P L Haroled
authors: PL
authors: Peter
authors: K
authors: K
authors: Rajesh
authors: P Jawahar
authors: PJ
authors: Babu
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D000083:Acetanilides / Q000097:blood* / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000378:metabolism* / Q000494:pharmacology; D002645:Chickens; D004347:Drug Interactions / Q000502:physiology; D004791:Enzyme Inhibitors / Q000097:blood / Q000494:pharmacology; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology; D008297:Male; D009924:Organ Culture Techniques; D010879:Piperazines / Q000097:blood* / Q000494:pharmacology; D011794:Quercetin / Q000097:blood* / Q000494:pharmacology; D000069458:Ranolazine; D051381:Rats; D017208:Rats, Wistar; D026941:Sodium Channel Blockers / Q000097:blood* / Q000494:pharmacology
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000083:Acetanilides; D000975:Antioxidants; D004791:Enzyme Inhibitors; D010879:Piperazines; D026941:Sodium Channel Blockers; D011794:Quercetin; D000069458:Ranolazine